跳至主要内容
临床试验/NCT01118507
NCT01118507已完成不适用

Trisomy of Chromosome 21 Diagnosis by High Output Sequencing of Foetal Circulating DNA in Mother Blood at First Trimester of Pregnancy.

Assistance Publique - Hôpitaux de Paris2 个研究点 分布在 1 个国家目标入组 976 人开始时间: 2010年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
976
试验地点
2
主要终点
The diagnostic performances of the quantification of the DNA resulting from the chromosome 21 by High output shotgun sequencing

研究概览

简要总结

Demonstrate that the High output shotgun sequencing of the foetal DNA in the maternal blood could allow a complete discrimination between the mothers of a trisomic fetus 21 or a DISOMIQUE foetus 21 from the first quarter of the pregnancy, and so to obtain a reliable alternative in invasive procedure.

详细描述

Justification of the research :

The trisomy 21 is the most frequent cause of handicap of genetic origin with an incidence of 1.3/1 000 births which increases with the maternal age. Several strategies of antenatal screening were developed. The High Authority of Health recently recommended to propose to the pregnant women a 1st trimester combined screening, realized between 11+0 and 13+6 weeks of amenorrhoea, associating measure of the NUCALE translucency and dosage in maternal serum : PAPP-A (Pregnancy Associated Plasma Protein A) and βhCG (free β human Chorionic 1st trimester Gonadotrophin). However, the sensibility of these screening tests is about 80 % for 5 % of positive false. The diagnosis of aneuploidy is then established on a population classified at high risk, by a foetal karyotype (requiring an invasive procedure : biopsy of trophoblast or amniocentesis). A positive screening increase maternal and medical anxiety. Furthermore, the inappropriate combination of the tests is at the origin of numerous useless invasive procedures (national rate of amniocentesis of 11 %), at risk of foetal losses (0,5 in 1 %). This inflation of invasive procedures leads to so many losses of not affected children as trisomic children and to a badly known maternal morbidity.

Several studies showed that 10 % of the free DNA found from the first quarter of the pregnancy in the maternal plasma is of foetal origin and that this DNA is specific of the foetal nuclear DNA of the current pregnancy. This opened the way of a possible not invasive antenatal diagnosis of the foetal aneuploidy which collided during the last 10 years with the performances limited by the isolation and by the sequencing of the foetal DNA in the maternal plasma. A new technique of analysis by broadband sequencing of the DNA circulating in the maternal blood for the diagnosis of the most frequent aneuploid the trisomy 21 of which was brought back(reported). The High-output shotgun sequencing of all the DNA circulating in the maternal blood, then the reading and the identification of all the chromosome sequences allows to analyze the quantity of DNA resulting from the supernumerary chromosome, without necessity of differentiating maternal and foetal DNA. On the basis of very recent works 10, this excess of sequences resulting specifically from the chromosome 21 foetal supernumerary allows a discrimination completes between trisomy 21 and disomy 21. However, this study analyzed only 9 cases of trisomy 21 and the sampling of maternal blood were realized after the amniocentesis or the choriocenteses, what could artificially have increased the quantity of circulating foetal DNA.

Objectives :

Demonstrate that the High output shotgun sequencing of the foetal DNA in the maternal blood could allow a complete discrimination between the mothers of a trisomic fetus 21 or a DISOMIQUE fetus 21 from the first quarter of the pregnancy, and so to obtain a reliable alternative in invasive procedure.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥ 18 years,
  • patient coming from one of multidisciplinary prenatal diagnosis center
  • having à high risk of trisomy of chromosome 21 estimated by combine screening > 1/250
  • 11 weeks of gestation or high
  • accepting invasive prenatal diagnosis of chromosomal abnormalities
  • accepting genetic analysis of blood circulating DNA
  • Patient accepting to sign the enlightened assent

排除标准

  • Patient of less than 18 years
  • combine risk < 1/250
  • refusing invasive prenatal diagnosis of chromosomal abnormalities
  • refusing genetic analysis of blood circulating DNA
  • Patient refusing to sign the enlightened assent

研究组 & 干预措施

TRISOMY

mothers of a trisomic fetus 21

NORMAL KARYOTYPE

mothers of DISOMIQUE foetus 21

结局指标

主要结局

The diagnostic performances of the quantification of the DNA resulting from the chromosome 21 by High output shotgun sequencing

时间窗: 24 MONTHS

The diagnostic performances(sensibility and specificity)of the quantification of the DNA resulting from the chromosome 21 by High-througput shotgun sequencing will be estimated in comparison with the results of the traditional cytogenetics obtained by culture of amniocytes or trophoblaste (gold standards).

次要结局

  • The time necessary for the treatments of samples:(24 MONTHS)
  • The cost by taking.(24 MONTHS)
  • The repeatability of the quantification:(24 MONTHS)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验